Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model.

Lozenski K, Kish-Catalone T, Pirrone V, Rando RF, Labib M, Wigdahl B, Krebs FC.

J Biomed Biotechnol. 2011;2011:941061. doi: 10.1155/2011/941061. Epub 2011 Oct 24.

2.

Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.

Catalone BJ, Kish-Catalone TM, Budgeon LR, Neely EB, Ferguson M, Krebs FC, Howett MK, Labib M, Rando R, Wigdahl B.

Antimicrob Agents Chemother. 2004 May;48(5):1837-47.

3.

Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection.

Thakkar N, Pirrone V, Passic S, Keogan S, Zhu W, Kholodovych V, Welsh W, Rando R, Labib M, Wigdahl B, Krebs FC.

Antimicrob Agents Chemother. 2010 May;54(5):1965-72. doi: 10.1128/AAC.00934-09. Epub 2010 Mar 15.

4.

Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection.

Thakkar N, Pirrone V, Passic S, Zhu W, Kholodovych V, Welsh W, Rando RF, Labib ME, Wigdahl B, Krebs FC.

Antimicrob Agents Chemother. 2009 Feb;53(2):631-8. doi: 10.1128/AAC.00866-08. Epub 2008 Dec 1.

5.

Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1.

Passic SR, Ferguson ML, Catalone BJ, Kish-Catalone T, Kholodovych V, Zhu W, Welsh W, Rando R, Howett MK, Wigdahl B, Labib M, Krebs FC.

Biomed Pharmacother. 2010 Dec;64(10):723-32. doi: 10.1016/j.biopha.2010.10.001. Epub 2010 Nov 4.

6.

A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea]).

D'Cruz OJ, Qazi S, Yiv S, Uckun FM.

Expert Opin Investig Drugs. 2012 Mar;21(3):265-79. doi: 10.1517/13543784.2012.655422. Epub 2012 Feb 1. Review.

PMID:
22292483
7.

Clinical development of microbicides for the prevention of HIV infection.

D'Cruz OJ, Uckun FM.

Curr Pharm Des. 2004;10(3):315-36. Review.

PMID:
14754390
8.

Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.

Kish-Catalone TM, Lu W, Gallo RC, DeVico AL.

Antimicrob Agents Chemother. 2006 Apr;50(4):1497-509.

9.

A 13-week subchronic intravaginal toxicity study of pokeweed antiviral protein in mice.

D'Cruz OJ, Waurzyniakt B, Uckun FM.

Phytomedicine. 2004;11(4):342-51.

PMID:
15185849
10.

Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety.

Lozenski K, Ownbey R, Wigdahl B, Kish-Catalone T, Krebs FC.

BMC Pharmacol Toxicol. 2012 Oct 1;13:9. doi: 10.1186/2050-6511-13-9.

11.

The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques.

Cole AM, Patton DL, Rohan LC, Cole AL, Cosgrove-Sweeney Y, Rogers NA, Ratner D, Sassi AB, Lackman-Smith C, Tarwater P, Ramratnam B, Ruchala P, Lehrer RI, Waring AJ, Gupta P.

PLoS One. 2010 Nov 29;5(11):e15111. doi: 10.1371/journal.pone.0015111.

12.

Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission.

Yang J, Li L, Jin H, Tan S, Qiu J, Yang L, Ding Y, Jiang ZH, Jiang S, Liu S.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1498-508. doi: 10.1089/AID.2012.0084. Epub 2012 Sep 11.

PMID:
22867271
14.

Preclinical evaluation of lime juice as a topical microbicide candidate.

Fletcher PS, Harman SJ, Boothe AR, Doncel GF, Shattock RJ.

Retrovirology. 2008 Jan 11;5:3. doi: 10.1186/1742-4690-5-3.

15.

Microbicides: a new hope for HIV prevention.

Nutan, Gupta SK.

Indian J Med Res. 2011 Dec;134(6):939-49. doi: 10.4103/0971-5916.92639. Review.

16.

Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.

Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR.

Antiviral Res. 2010 Dec;88 Suppl 1:S55-66. doi: 10.1016/j.antiviral.2010.09.006.

PMID:
21109069
17.

Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge.

Fernández-Romero JA, Abraham CJ, Rodriguez A, Kizima L, Jean-Pierre N, Menon R, Begay O, Seidor S, Ford BE, Gil PI, Peters J, Katz D, Robbiani M, Zydowsky TM.

Antimicrob Agents Chemother. 2012 Jan;56(1):358-68. doi: 10.1128/AAC.05461-11. Epub 2011 Nov 7.

18.

Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G.

Catalone BJ, Miller SR, Ferguson ML, Malamud D, Kish-Catalone T, Thakkar NJ, Krebs FC, Howett MK, Wigdahl B.

Biomed Pharmacother. 2005 Sep;59(8):430-7.

PMID:
16154721
19.

PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.

Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC.

J Infect Dis. 2006 Jan 1;193(1):27-35. Epub 2005 Nov 17.

20.

Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro.

Lai BE, Geonnotti AR, Desoto MG, Montefiori DC, Katz DF.

Antiviral Res. 2010 Nov;88(2):143-51. doi: 10.1016/j.antiviral.2010.08.006. Epub 2010 Aug 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk